AI assistant
Coloplast — M&A Activity 2007
Jun 14, 2007
3358_iss_2007-06-14_cb183099-bf1d-4d5a-b1e6-be6420587f8f.pdf
M&A Activity
Open in viewerOpens in your device viewer
Stock Exchange Announcement no. 10/2007 8 June 2007
Coloplast has completed the divestment of its brachytherapy business
The divestment of Coloplast's brachytherapy business to Brachysales, Inc., now known as Core Oncology, Inc., has been completed on 8 June 2007 in accordance with the conditions described in Coloplast's stock exchange announcement no. 3/2007 of 20 February 2007.
The transaction includes an independent sales force as well as Coloplast's manufacturing facility in Oklahoma, USA, also known as Mills Biopharmaceuticals LLC.
The brachytherapy business is reported in the Group's income statement as net profit from discontinued operations. The transaction has an insignificant impact on Coloplast's results.
As the brachytherapy business encompassed approximately 1% of Coloplast's Group revenue, the divestment will not affect the expectations for 2006/07 or the long-term targets for 2012.
Lene Skole Executive Vice President, CFO
Further information
Investors and financial analysts
Jørgen Fischer Ravn Head of Investor relations Tel. +45 3085 1308 E-mail: [email protected]
Press and the media
Jens Tovborg Jensen Head of Media relations Tel. +45 3085 1922 E-mail: [email protected]
This announcement is available in a Danish and an English language version. In the event of discrepancies, the Danish version shall prevail.